Chazard Emmanuel, Boudry Augustin, Beeler Patrick Emanuel, Dalleur Olivia, Hubert Hervé, Tréhou Eric, Beuscart Jean-Baptiste, Bates David Westfall
Univ. Lille, CHU Lille, ULR 2694 - METRICS, CERIM, Public health dept, F-59000, Lille, France.
Division of Occupational and Environmental Medicine, Epidemiology, Biostatistics and Prevention Institute, University Hospital Zurich & University of Zurich, Zurich, Switzerland.
JMIR Med Inform. 2021 Jan 20;9(1):e20862. doi: 10.2196/20862.
Drug-drug interactions (DDIs) involving vitamin K antagonists (VKAs) constitute an important cause of in-hospital morbidity and mortality. However, the list of potential DDIs is long; the implementation of all these interactions in a clinical decision support system (CDSS) results in over-alerting and alert fatigue, limiting the benefits provided by the CDSS.
To estimate the probability of occurrence of international normalized ratio (INR) changes for each DDI rule, via the reuse of electronic health records.
An 8-year, exhaustive, population-based, historical cohort study including a French community hospital, a group of Danish community hospitals, and a Bulgarian hospital. The study database included 156,893 stays. After filtering against two criteria (at least one VKA administration and at least one INR laboratory result), the final analysis covered 4047 stays. Exposure to any of the 145 drugs known to interact with VKA was tracked and analyzed if at least 3 patients were concerned. The main outcomes are VKA potentiation (defined as an INR≥5) and VKA inhibition (defined as an INR≤1.5). Groups were compared using the Fisher exact test and logistic regression, and the results were expressed as an odds ratio (95% confidence limits).
The drugs known to interact with VKAs either did not have a statistically significant association regarding the outcome (47 drug administrations and 14 discontinuations) or were associated with significant reduction in risk of its occurrence (odds ratio<1 for 18 administrations and 21 discontinuations).
The probabilities of outcomes obtained were not those expected on the basis of our current body of pharmacological knowledge. The results do not cast doubt on our current pharmacological knowledge per se but do challenge the commonly accepted idea whereby this knowledge alone should be used to define when a DDI alert should be displayed. Real-life probabilities should also be considered during the filtration of DDI alerts by CDSSs, as proposed in SPC-CDSS (statistically prioritized and contextualized CDSS). However, these probabilities may differ from one hospital to another and so should probably be calculated locally.
涉及维生素K拮抗剂(VKA)的药物相互作用(DDI)是住院患者发病和死亡的重要原因。然而,潜在的药物相互作用列表很长;在临床决策支持系统(CDSS)中实施所有这些相互作用会导致过度警报和警报疲劳,从而限制了CDSS所提供的益处。
通过重新利用电子健康记录,估计每条DDI规则导致国际标准化比值(INR)变化的发生概率。
一项为期8年的、详尽的、基于人群的历史性队列研究,研究对象包括一家法国社区医院、一组丹麦社区医院和一家保加利亚医院。研究数据库包含156,893次住院记录。在根据两个标准进行筛选(至少一次VKA给药和至少一次INR实验室检测结果)后,最终分析涵盖4047次住院记录。如果至少有3名患者涉及,则追踪并分析其是否接触过已知与VKA相互作用的145种药物中的任何一种。主要结局为VKA增强(定义为INR≥5)和VKA抑制(定义为INR≤1.5)。使用Fisher精确检验和逻辑回归对组间进行比较,结果以比值比(95%置信区间)表示。
已知与VKA相互作用的药物,要么在结局方面没有统计学上的显著关联(47次给药和14次停药),要么与结局发生风险的显著降低相关(18次给药和21次停药的比值比<1)。
所获得的结局概率并非基于我们目前的药理学知识体系所预期的概率。这些结果本身并未对我们目前的药理学知识产生怀疑,但确实对仅依据该知识来定义何时应显示DDI警报这一普遍接受的观点提出了挑战。正如SPC-CDSS(统计优先和情境化的CDSS)所提议的,在CDSS对DDI警报进行筛选时,也应考虑实际发生概率。然而,这些概率可能因医院而异,因此可能需要在当地进行计算。